Sinco Pharmaceutical Holdings (HKSE:06833) Net Income (Continuing Operations) : HK$46 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Sinco Pharmaceutical Holdings Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Sinco Pharmaceutical Holdings's Net Income (Continuing Operations) for the six months ended in Dec. 2023 was HK$25 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$46 Mil.

Sinco Pharmaceutical Holdings Net Income (Continuing Operations) Historical Data

The historical data trend for Sinco Pharmaceutical Holdings's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinco Pharmaceutical Holdings Net Income (Continuing Operations) Chart

Sinco Pharmaceutical Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

26.21

140.04

165.41

77.57

46.32

Sinco Pharmaceutical Holdings Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income (Continuing Operations)	Get a 7-Day Free Trial														73.23	72.59	8.42	21.43	24.89

Sinco Pharmaceutical Holdings Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$46 Mil.

Sinco Pharmaceutical Holdings (HKSE:06833) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Sinco Pharmaceutical Holdings Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Sinco Pharmaceutical Holdings's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinco Pharmaceutical Holdings (HKSE:06833) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sinco Pharmaceutical Holdings Ltd (HKSE:06833) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1700, North Section of Tianfu Avenue, E5-1805, Global Centre, High-Tech Zone, Chengdu, Sichuan Province, Chengdu, CHN

Website

https://www.sinco-pharm.com

Sinco Pharmaceutical Holdings Ltd is an investment holding company engaged in the provision of comprehensive marketing, promotion, and channel management service for imported pharmaceutical products and medical devices in China. The company has three operating segments; the sale of imported pharmaceutical products segment, the research and manufacturing of aesthetic medicine segment, and the medical beauty services segment. Its product offering includes Human albumin solutions and Antibiotics like Axetine and Medocef.

Executives

Huang Zhijian	2305 Beneficiary of a trust
Fullwealth Holdings Limited	2201 Interest of corporation controlled by you
Risun Investments Limited	2101 Beneficial owner
Wickhams Cay Trust Company Limited	2301 Trustee
Huang Xiangbin	2307 Founder of a discretionary trust who can infl

Sinco Pharmaceutical Holdings (HKSE:06833) Headlines

No Headlines